Clinical trial • Phase IV • Neurology | Musculoskeletal

Autologous bone marrow-derived stem cells for Amyotrophic lateral sclerosis

Phase IV trial of Autologous bone marrow-derived stem cells for Amyotrophic lateral sclerosis. 100 participants.

Overview

Trial Therapeutic Area
Neurology | Musculoskeletal
Trial Disease
Amyotrophic lateral sclerosis
Trial Stage
Phase IV
Drug Modality
Cell therapy

Key dates

Initial CTIS Submission Date
08-10-2024
First CTIS Authorization Date
05-11-2024

Trial design

Phase IV trial across 2 sites in Spain.

Target Sample Size
100
Trial Duration For Participant
1827

Eligibility

Recruits 100 Vulnerable population not selected; no details on consent or assent provided..

Vulnerable Population
Vulnerable population not selected; no details on consent or assent provided.

Recruitment

Planned Sample Size
100
Recruitment Window Months
60
Consent Approach
No information provided on informed consent or assent; not specified.

Geography

Total Number Of Sites
2
Total Number Of Participants
100

Spain

Earliest CTIS Part Ii Submission Date
17-10-2024
Latest Decision Or Authorization Date
05-11-2024
Processing Time Days
19
Number Of Sites
2
Number Of Participants
100

Sites

Site Name
Hospital General Universitario Dr. Balmis
Department Name
Neurology
Contact Person Name
Carmen Díaz Marín
Contact Person Email
carmina.diaz.marin@gmail.com
Site Name
University Clinical Hospital Virgen De La Arrixaca
Department Name
Hematology
Contact Person Name
Miguel Blanquer Blanquer
Contact Person Email
miguelblanquer@gmail.com

Sponsor

Primary sponsor

Full Name
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Organisation Type
Educational Institution
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
Autologous bone marrow-derived stem cells (intramuscular infusion)
Active Substance
Autologous bone marrow-derived stem cells
Modality
Cell therapy
Routes Of Administration
Intramuscular
Route
Intramuscular

Related trials

Other published trials that may interest you.